Advancement in nanotechnology-based approaches for the treatment and diagnosis of hypercholesterolemia
Source abstract
Abstract
Cardiovascular diseases have been the major cause of mortality and morbidity all over the world accounting for more than 80% of the deaths from heart attacks and strokes. Hypercholesterolemia, an autosomal disorder of lipoprotein metabolism is one of the foremost causes of CVDs. An increased level of low-density lipoprotein cholesterol (LDL-C) in the plasma results in the rise of incidence rates in disease patients. Several conventional and combinational therapies have been proposed for lowering the LDL-C levels in the blood. These therapeutic agents are designed to target some crucial molecules that participates in the lipid metabolism such as apolipoprotein B, HMGCoA reductase, proprotein convertase subtilisin/kexin 9, etc. Although these therapies are effective but are associated with certain side effects. This article presents an overview on different conventional and nanotechnology-based approaches for the treatment and diagnosis of hypercholesterolemia. Numerous nanomaterial-based therapies including polymeric nanoparticles, cationic lipids, liposomes, dendrimers and inorganic nanoparticles have been discussed in lowering the cholesterol level along with recent advancement in diagnosis and imaging.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Computational Drug Discovery Methods · Lipoproteins and Cardiovascular Health · Atherosclerosis and Cardiovascular Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biotechnology, The IIS University
Department of Biotechnology, Central University of Rajasthan
Department of Endocrinology, SMS Medical College and Hospitals
Department of Chemistry, University of Delhi
Funding
Science and Engineering Research Board
References (57)
Show source-provided references
1. 10.1161/ATVBAHA.115.30669710.1161/ATVBAHA.115.306697 ↗
2. 10.1016/j.foodchem.2016.05.02910.1016/j.foodchem.2016.05.029 ↗
3. 10.1161/CIR.000000000000015710.1161/CIR.0000000000000157 ↗
4. 10.1161/ATVBAHA.108.17956410.1161/ATVBAHA.108.179564 ↗
5. 10.1093/aje/kwh23610.1093/aje/kwh236 ↗
6. 10.7555/JBR.29.2015006710.7555/JBR.29.20150067 ↗
7. 10.1007/s40119-015-0037-z10.1007/s40119-015-0037-z ↗
8. 10.1161/CIRCULATIONAHA.111.04252310.1161/CIRCULATIONAHA.111.042523 ↗
9. 10.1136/bmj.326.7404.142310.1136/bmj.326.7404.1423 ↗
10. 10.4103/0974-2069.13247810.4103/0974-2069.132478 ↗
11. 10.4065/80.5.58710.4065/80.5.587 ↗
12. 10.1016/j.atherosclerosis.2008.02.00910.1016/j.atherosclerosis.2008.02.009 ↗
13. 10.1016/S0140-6736(01)07098-210.1016/S0140-6736(01)07098-2 ↗
14. 10.1038/nrcardio.2011.210.1038/nrcardio.2011.2 ↗
15. 10.1345/aph.1K06510.1345/aph.1K065 ↗
16. 10.1073/pnas.050165210210.1073/pnas.0501652102 ↗
17. 10.1093/eurheartj/ehv17410.1093/eurheartj/ehv174 ↗
18. 10.1016/S0140-6736(12)60771-510.1016/S0140-6736(12)60771-5 ↗
19. 10.1016/j.jacl.2012.04.06610.1016/j.jacl.2012.04.066 ↗
20. 10.1371/journal.pone.001068210.1371/journal.pone.0010682 ↗
21. 10.1038/363446a010.1038/363446a0 ↗
22. 10.1146/annurev-biochem-063011-09244910.1146/annurev-biochem-063011-092449 ↗
23. 10.1016/S0022-1759(00)00188-510.1016/S0022-1759(00)00188-5 ↗
24. 10.1074/jbc.M116.71773610.1074/jbc.M116.717736 ↗
25. 10.1161/01.CIR.0000141730.65972.9510.1161/01.CIR.0000141730.65972.95 ↗
26. 10.1056/NEJMoa06118910.1056/NEJMoa061189 ↗
27. Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia 2011; [cited 8 Dec 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT00263081
28. 10.1161/CIRCULATIONAHA.110.97528410.1161/CIRCULATIONAHA.110.975284 ↗
29. 10.1016/j.metabol.2004.01.01710.1016/j.metabol.2004.01.017 ↗
30. 10.2174/09298670677636100310.2174/092986706776361003 ↗
31. 10.1016/j.tim.2014.04.01010.1016/j.tim.2014.04.010 ↗
32. 10.1517/14712598.2013.75870610.1517/14712598.2013.758706 ↗
33. 10.1017/S000711451100470310.1017/S0007114511004703 ↗
34. 10.1016/j.atherosclerosis.2006.10.00110.1016/j.atherosclerosis.2006.10.001 ↗
35. 10.1002/pds.385810.1002/pds.3858 ↗
36. 10.1194/jlr.M05740610.1194/jlr.M057406 ↗
37. 10.1111/j.2042-7158.2011.01273.x10.1111/j.2042-7158.2011.01273.x ↗
38. 10.5185/amlett.2012.icnano.15310.5185/amlett.2012.icnano.153 ↗
39. 10.1590/S1984-8250201500020002410.1590/S1984-82502015000200024 ↗
40. 10.1155/2011/81460610.1155/2011/814606 ↗
41. 10.1016/S1525-0016(16)35388-610.1016/S1525-0016(16)35388-6 ↗
42. 10.1039/b900880b10.1039/b900880b ↗
43. 10.1021/mp300650y10.1021/mp300650y ↗
44. 10.1021/acs.biomac.5b0074610.1021/acs.biomac.5b00746 ↗
45. 10.2174/156720181366615110910271810.2174/1567201813666151109102718 ↗
46. 10.1073/pnas.080543410510.1073/pnas.0805434105 ↗
47. 10.1007/s13346-013-0161-z10.1007/s13346-013-0161-z ↗
48. Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia 2012; [cited 16 Jan 2017]. Available from: http://investors.alnylam.com/releasedetail.cfm?ReleaseID =734334
49. 10.1016/j.atherosclerosis.2015.07.03210.1016/j.atherosclerosis.2015.07.032 ↗
50. 10.1016/j.ijpharm.2010.04.03910.1016/j.ijpharm.2010.04.039 ↗
51. 10.1038/nrd219710.1038/nrd2197 ↗
52. 10.1016/j.colsurfb.2012.05.01910.1016/j.colsurfb.2012.05.019 ↗
53. 10.1049/iet-nbt.2014.005710.1049/iet-nbt.2014.0057 ↗
54. 10.1016/j.ejps.2008.06.01310.1016/j.ejps.2008.06.013 ↗
55. Ganesh K, Archana D, Preeti K. Galactosylated albumin nanoparticles of simvastatin. Iranian J Pharm Res. 2015;14:407–415.
56. 10.1016/j.ab.2014.08.03110.1016/j.ab.2014.08.031 ↗
57. Zhang H. 64Cu-DTPA-CLIO-VT680. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US); 2008:2004–2013.